Real time continuous glucose monitoring in high‐risk people with insulin‐requiring type 2 diabetes: A randomised controlled trial
Authors' conclusion
Real-time CGM use in a supportive treat-to-target model of care likely improves glycaemia in a population with insulin-treated T2D and elevated HbA1c.
Study context
- Population
- Adults with insulin-requiring T2D using ≥0.2 units/kg/day of insulin and HbA1c ≥64 mmol/mol (8.0%), predominantly indigenous (Māori), New Zealand; median age 53, 57% female54% Māori
- Participants
- 67 adults
- Comparison
- Real-time continuous glucose monitoring (rtCGM) vs control
- Primary endpoint
- TIR (3.9-10 mmol/L), with blinded rtCGM in the control group
- Follow-up
- Weeks 10-12
Methodological detailsmulticentre, 2-week blinded CGM run-in
- Multicentre
- 2-week blinded CGM run-in
Primary result
TIR
Baseline-adjusted between-group difference
10.4 %
95% CI −0.9 to 21.7
P = 0.070
Between rtCGM and SMBG
baseline-adjusted between-group difference 10.4 % (95% CI −0.9 to 21.7); P = 0.070
As reported in the abstract
- rtCGM: mean (SD) TIR increased from 37 (24)% to 53 (24)%
- Δ 13%; 95% CI 4.2 to 22; P = 0.007
- SMBG: TIR did not change, 45 (21)% to 45 (25)%
- Δ 2.5%, 95% CI −6.1 to 11, P = 0.84
Further findings
HbA1c · baseline to 12 weeks
Baseline rtCGM 85 (18) mmol/mol (10.0 [1.7]%) · SMBG 81 (12) mmol/mol (9.6 [1.1]%)
End rtCGM 8.0 [1.4]% · SMBG 8.1 [1.2]%
- HbA1c — HbA1c decreased in both groups
- P < 0.001 for both
Safety
- There were no severe hypoglycaemic or ketoacidosis events in either group
Original publication
Real time continuous glucose monitoring in high‐risk people with insulin‐requiring type 2 diabetes: A randomised controlled trial. Diabet Med. Published 17 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →